Posted on 05/08/2010 in Scientific PerkinElmer has enhanced its cellular imaging business activities with the purchase of the in vivo molecular imaging technology specialist VisEn Medical.
The newly-acquired firm was founded in 2000 and offers products such as fluorescence agents and fluorescence molecular tomographic imaging systems, which can be used to identify biomarkers and test therapeutic efficacy.
By purchasing VisEn, PerkinElmer will be able to offer an increased range of preclinical research products, allowing for the development of more effective new drugs.
Currently, VisEn products are utilised in research into a range of diseases, such as cancer and inflammation, as well as cardiovascular and pulmonary conditions.
Richard Eglen, president of bio-discovery at PerkinElmer, said: "This acquisition broadens our product portfolio along the drug discovery pipeline ... through the addition of proprietary chemistries in the emerging and fast-growing space of translational biomarker reagents."
PerkinElmer recently enhanced its Columbus 2.1 and Volocity 5.3.2 imaging software by adding 3D imaging functionality for greater ease of use. Other news stories from 05/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
